Acute Myeloid Leukemia
Mostrando 13-24 de 433 artigos, teses e dissertações.
-
13. Pesquisa em doenças inflamatórias intestinais no Brasil: um passo à frente rumo ao cuidado dos pacientes
Maytenus distichophylla is a medicinal species used in Northeast of Brazil. The hexane (HE), chloroform (CE), ethyl acetate (EAE) and methanol (ME) extracts and compounds from its roots were evaluated for their protective activity against Staphylococcus aureus and Candida albicans. The cytotoxicity for chronic myeloid leukemia (K562), acute monocytic leukemi
Arq. Gastroenterol.. Publicado em: 2020-09
-
14. CONSTITUENTS FROM ROOTS OF Maytenus distichophylla, ANTIMICROBIAL ACTIVITY AND TOXICITY FOR CELLS AND Caenorhabditis elegans
Maytenus distichophylla is a medicinal species used in Northeast of Brazil. The hexane (HE), chloroform (CE), ethyl acetate (EAE) and methanol (ME) extracts and compounds from its roots were evaluated for their protective activity against Staphylococcus aureus and Candida albicans. The cytotoxicity for chronic myeloid leukemia (K562), acute monocytic leukemi
Quím. Nova. Publicado em: 2020-09
-
15. Intravenous ferric carboxymaltose for the treatment of iron deficiency anaemia – reply
Abstract Introduction Hematologists deal every day with high mortality rates of acute leukemia patients. Many times these patients need Intensive Care Unit (ICU) support and some general ICU teams believe that these patients have a much greater chance of dying than patients with other pathologies. In Brazil, data related to mortality rates and ICUs for acut
Hematol., Transfus. Cell Ther.. Publicado em: 2020-03
-
16. A case of neurocognitive deficit strongly related to dasatinib therapy
Abstract Introduction Hematologists deal every day with high mortality rates of acute leukemia patients. Many times these patients need Intensive Care Unit (ICU) support and some general ICU teams believe that these patients have a much greater chance of dying than patients with other pathologies. In Brazil, data related to mortality rates and ICUs for acut
Hematol., Transfus. Cell Ther.. Publicado em: 2020-03
-
17. A case of multiple myeloma and synchronous liposarcoma
Abstract Introduction Hematologists deal every day with high mortality rates of acute leukemia patients. Many times these patients need Intensive Care Unit (ICU) support and some general ICU teams believe that these patients have a much greater chance of dying than patients with other pathologies. In Brazil, data related to mortality rates and ICUs for acut
Hematol., Transfus. Cell Ther.. Publicado em: 2020-03
-
18. Predictors of mortality among patients with acute leukemias admitted to an intensive care unit specialized in patients with hematological disease at a Brazilian hospital
Abstract Introduction Hematologists deal every day with high mortality rates of acute leukemia patients. Many times these patients need Intensive Care Unit (ICU) support and some general ICU teams believe that these patients have a much greater chance of dying than patients with other pathologies. In Brazil, data related to mortality rates and ICUs for acut
Hematol., Transfus. Cell Ther.. Publicado em: 2020-03
-
19. Myeloid sarcoma on the scalp of a patient with acute myeloid leukemia
An. Bras. Dermatol.. Publicado em: 09/12/2019
-
20. Differential effects of the methylenetetrahydrofolate reductase polymorphisms (C677T and A1298C) on hematological malignancies among Latinos: a meta-analysis
Abstract Our objective was to determine the association between the methylenetetrahydrofolate reductase polymorphisms (C677T and A1298C) and the risk of developing acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), acute myeloid leukemia (AML), and multiple myelomas (MM) in Latinos. PubMed, SCOPUS, EBSCO, LILACS, and other Latin-specific dat
Genet. Mol. Biol.. Publicado em: 14/11/2019
-
21. Cytogenetic abnormalities, WHO classification, and evolution of children and adolescents with acute myeloid leukemia
ABSTRACT Objectives: To describe cytogenetic and molecular abnormalities observed in children and adolescents with acute myeloid leukemia (AML), classify AML according to the World Health Organization (WHO) classifications from 2008 and 2016, and evaluate the prognosis according to clinical characteristics and cytogenetic abnormalities. Methods: A retrospe
Hematol., Transfus. Cell Ther.. Publicado em: 10/10/2019
-
22. Targeted therapy with a selective BCL-2 inhibitor in older patients with acute myeloid leukemia
ABSTRACT Background: Older patients with acute myeloid leukemia are particularly difficult to treat, as they have a high risk of comorbidities, poor performance status and less tolerability to chemotherapy, as well as a more aggressive disease biology, responsible for the resistance to treatment. There is a need to explore novel therapeutic agents that are
Hematol., Transfus. Cell Ther.. Publicado em: 10/06/2019
-
23. CCAAT/enhancer-binding protein alpha (CEBPA) gene haploinsufficiency does not alter hematopoiesis or induce leukemia in Lck-CALM/AF10 transgenic mice
Although rare, CALM/AF10 is a chromosomal rearrangement found in immature T-cell acute lymphoblastic leukemia (T-ALL), acute myeloid leukemia, and mixed phenotype acute leukemia of T/myeloid lineages with poor prognosis. Moreover, this translocation is detected in 50% of T-ALL patients with gamma/delta T cell receptor rearrangement, frequently associated wit
Braz J Med Biol Res. Publicado em: 27/05/2019
-
24. Role of physical function in predicting short-term treatment outcome in Egyptian acute myeloid leukemia patients: a single center experience
Abstract Background Acute myeloid leukemia (AML) is a potentially fatal hematological disease. Along with disease-related factors, patient-related factors, in particular age, are a strong predictor of outcome that influence treatment decisions. Many acute myeloid leukemia risk stratification models have been developed to predict the outcome of intensive che
Hematol., Transfus. Cell Ther.. Publicado em: 15/04/2019